Trials / Conditions / Refractory Differentiated Thyroid Gland Carcinoma
Refractory Differentiated Thyroid Gland Carcinoma
5 registered clinical trials studyying Refractory Differentiated Thyroid Gland Carcinoma — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer NCT06959641 | Northwestern University | Phase 2 |
| Recruiting | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer NCT06475989 | ECOG-ACRIN Cancer Research Group | Phase 3 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated T NCT03914300 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer NCT01208051 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |